Carfilzomib injection bulk supplier for pharma manufacturers

Carfilzomib Injection 60mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 60mg/vial

Reference Brands: Kyprolis

Carfilzomib injection is used alone to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma (a type of bone marrow cancer) in patients who have received 1 or more previous treatments.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Carfilzomib (Kyprolis) is regulated in the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality compliant with GMP and MDR standards. In the US, FDA approval involved extensive clinical validation, safety assessments, and GMP compliance. In the EU, CE marking certifies conformity with MDR standards. These products undergo validation, stability testing, and audits, supported by comprehensive documentation including safety profiles, clinical trial data, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring regulatory compliance guarantees access to high-quality carfilzomib formulations, supporting effective treatment for multiple myeloma worldwide and improving patient outcomes.

Carfilzomib Injection — third party manufacturing & bulk supply

Carfilzomib Injection 60mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Carfilzomib Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Carfilzomib Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Carfilzomib Injection →

Back to Listing

Frequently Asked Questions

Carfilzomib injection is listed as Injection in 60mg/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Carfilzomib injection is referenced against Kyprolis. Reference brands are shown for identification only and remain the property of their respective trademark owners.